A federal judge has dealt a major setback to the “indirect purchaser” plaintiffs in the massive antitrust litigation over the marketing of Wellbutrin XL, a popular anti-depressant drug, by tossing out most of the claims on standing grounds.

The plaintiffs, a group of employee benefit plans, were aiming to pursue the case as a class action alleging claims under the consumer protection laws of 41 states and the antitrust laws of 23 states.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]